Pfizer's Sickle Cell Strategy Stumbles: Inclacumab Fails Phase III Oxbryta Withdrawn

Explore the latest setbacks for Pfizer's sickle cell disease portfolio as its investigational P-selectin inhibitor, inclacumab, fails to meet its primary endpoint